<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669068</url>
  </required_header>
  <id_info>
    <org_study_id>HRC-ENDOHEM-02</org_study_id>
    <nct_id>NCT03669068</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: THE ENDOHEM REGISTRY</brief_title>
  <official_title>Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: A Prospective, Multicentre, and Observational Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Central de Asturias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Viladecans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Avilés</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General de Villalba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General de Granollers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study evaluates the safety of gastrointestinal endoscopy in patients on&#xD;
      oral anticoagulants (Vitamin K antagonists, rivaroxaban, dabigatran, edoxaban, and apixaban).&#xD;
      This registry aims to assess the incidence, characteristics and risk factors for&#xD;
      cardiovascular and bleeding events associated with an endoscopic procedure. Besides, it aims&#xD;
      to evaluate the differences between Vitamin K antagonists and DOACs users and to estimate the&#xD;
      impact of anticoagulation withdrawal time on the primary and secondary outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of Cardiovascular events</measure>
    <time_frame>3 months</time_frame>
    <description>Nº of patients during the study period presenting with a cardiovascular event, defined as any of the following entities: pulmonary thromboembolism, venous thromboembolism, acute coronary syndrome, arterial peripheral embolism or cerebrovascular accident.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of therapeutic endoscopy-related gastrointestinal bleeding</measure>
    <time_frame>3 months</time_frame>
    <description>Nº of patients during the study period presenting with therapeutic endoscopy-related gastrointestinal bleeding</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1602</enrollment>
  <condition>Gastrointestinal Bleeding</condition>
  <condition>Cardiovascular Complication</condition>
  <condition>Anticoagulants; Circulating, Hemorrhagic Disorder</condition>
  <condition>Gastrointestinal Endoscopy</condition>
  <arm_group>
    <arm_group_label>Elective endoscopy</arm_group_label>
    <description>Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastrointestinal bleeding</arm_group_label>
    <description>Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrointestinal endoscopy</intervention_name>
    <description>Two separated groups will be included in the registry:&#xD;
Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.&#xD;
Patients undergoing elective gastrointestinal endoscopy.</description>
    <arm_group_label>Elective endoscopy</arm_group_label>
    <arm_group_label>Gastrointestinal bleeding</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on oral anticoagulants (Vitamin K antagonist, apixaban, edoxaban, rivaroxaban or&#xD;
        dabigatran)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years.&#xD;
&#xD;
          -  Patients with preoperative use of oral anticoagulants (Vitamin K antagonist, apixaban,&#xD;
             edoxaban, rivaroxaban or dabigatrán) undergoing gastrointestinal endoscopy.&#xD;
&#xD;
          -  Patients on oral anticoagulants (Vitamin K antagonist, apixaban, edoxaban, rivaroxaban&#xD;
             or dabigatran) presenting with gastrointestinal bleeding, regardless of receiving&#xD;
             gastrointestinal endoscopy.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Negative to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 8, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Enrique Rodríguez de Santiago</investigator_full_name>
    <investigator_title>Principal Investigator. MSc. Gastroenterologist</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal endoscopy</keyword>
  <keyword>Oral anticoagulants</keyword>
  <keyword>Gastrointestinal bleeding</keyword>
  <keyword>Cardiovascular event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Available. Timeframe: 2018-2021</ipd_time_frame>
    <ipd_access_criteria>Accredited researchers. The protocol is available in Spanish and will be provided by contacting the principal investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

